Out of the 11 (1.7%) DKA cases infected with COVID-19 who were taking SGLT2 inhibitors, two patient [18.2%] were diagnosed with SGLT2-associated euglycemic DKA [blood glucose < 250 mg/dl at presentation] [16, 48]; in addition to seven patients who had gestational diabetes mellitus [53, 65, 70]. The gene discussed is SLC5A2; the disease is COVID-19.